AI Article Synopsis

  • Dupilumab significantly improved symptoms and measures of airway mucus hypersecretion and airway dimensions in patients with moderate-to-severe asthma over a 48-week treatment period.
  • The study included 28 adults and utilized assessments like the CASA-Q and CT scans to evaluate clinical effects.
  • Results indicated that 64% of patients showed noticeable improvement, highlighting dupilumab's effectiveness in managing asthma symptoms and airway inflammation.

Article Abstract

Background: Dupilumab has clinical effects in patients with moderate-to-severe asthma. When considering interleukin (IL)-4 and IL-13 signaling, effects of dupilumab on airway mucus hypersecretion and airway remodeling are expected, but they have been reported in only a few short-term studies. Its efficacy for airway hyperresponsiveness (AHR) remains unknown. We comprehensively assessed the efficacy of dupilumab, especially for subjective and objective measures of airway mucus hypersecretion and airway dimensions in moderate-to-severe asthmatic patients.

Methods: In 28 adult patients with moderate-to-severe uncontrolled asthma, the comprehensive efficacy of 48-week dupilumab treatment, including the Cough and Sputum Assessment Questionnaire (CASA-Q), radiological mucus scores and airway dimensions on computed tomography (CT), was assessed prospectively. Treatment responsiveness to dupilumab was analyzed.

Results: With 48-week dupilumab treatment, all four cough and sputum domain scores of CASA-Q improved significantly. Radiological mucus scores and airway wall thickening on CT were significantly decreased. The decreases in mucus scores were significantly associated with improvements in Asthma Control Questionnaire scores, Asthma Quality of Life Questionnaire (AQLQ) overall scores, airway obstruction, and airway type 2 inflammation. When defined by > 0.5 improvement in AQLQ overall scores, 18 patients (64%) were identified as responders.

Conclusions: Dupilumab reversed subjective and objective measures of airway mucus hypersecretion and some aspects of airway remodeling in patients with moderate-to-severe uncontrolled asthma.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.alit.2024.02.002DOI Listing

Publication Analysis

Top Keywords

patients moderate-to-severe
16
airway
13
hypersecretion airway
12
airway mucus
12
mucus hypersecretion
12
mucus scores
12
scores airway
12
efficacy dupilumab
8
dupilumab airway
8
airway wall
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!